SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-24-002880
Filing Date
2024-03-20
Accepted
2024-03-20 16:32:31
Documents
2
Period of Report
2024-03-18

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 4621
2 POA jumsteadpoa.txt EX-24 3383
  Complete submission text file 0001562180-24-002880.txt   9734
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O G1 THERAPEUTICS, INC. 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address
Umstead John W. V (Reporting) CIK: 0001967910 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38096 | Film No.: 24768212